Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00694) | |||||
---|---|---|---|---|---|
Name |
Trametinib
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Trametinib; 871700-17-3; GSK1120212; Mekinist; GSK-1120212; JTP 74057; JTP-74057; GSK 1120212; Trametinib (GSK1120212); N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide; GSK212; UNII-33E86K87QN; TMT212; CHEBI:75998; TMT-212; 33E86K87QN; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide; Trametinib [USAN:INN]; trametinibum; N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)acetamide; N-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl}phenyl)acetamide; Trametinib (USAN); Trametinib (GSK1120212JTP 74057); SCHEMBL170938; C26H23FIN5O4; GTPL6495; QCR-39; GSK1120212 (Trametinib); CHEMBL2103875; EX-A022; BCPP000218; DTXSID901007381; HMS3295I05; HMS3656J11; AOB87707; BCP02307; ABP000312; BDBM50531540; MFCD17215075; NSC758246; NSC800956; RW4149; ZINC43100709; AKOS015850628; AM90271; CCG-264976; CS-0060; DB08911; EX-5957; NSC-758246; NSC-800956; SB16553; NCGC00263180-01; NCGC00263180-07; NCGC00263180-14; AC-25891; AK174783; AS-19382; HY-10999; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; AB0008115; FT-0688438; SW218089-2; A11029; A25168; D10175; GSK1120212 - JTP-74057; S-7800; GSK-1120212/GSK1120212/; GSK1120212,JTP-74057, GSK212; SR-01000941589; A1-01871; J-523325; Q7833138; SR-01000941589-1; BRD-K12343256-001-01-4; Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)-; Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-; N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; N-[3-[3-Cyclopropyl-5-[(2-Fluoro-4-Iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2h)-yl]phe nyl]acetamide; N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide; N-{3-[3-Cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}ethanimidic acid; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Melanoma | ICD-11: 2C30 | [1] | ||
PubChem CID | |||||
Formula |
C26H23FIN5O4
|
||||
Canonical SMILES |
CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC=CC(=C4)NC(=O)C)C5CC5
|
||||
InChI |
1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
|
||||
InChIKey |
LIRYPHYGHXZJBZ-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=11707110"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 615.4 | Topological Polar Surface Area | 102 | |
XlogP | 3.4 | Complexity | 1090 | ||
Heavy Atom Count | 37 | Rotatable Bond Count | 5 | ||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 6 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Trametinib 0.5 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Mannitol; Ferric oxide red; Ferric oxide yellow; Croscarmellose sodium; Polysorbate 80; Silicon dioxide; Hypromelloses; Microcrystalline cellulose; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Polysorbate 80 | DIG Info | Prostaglandin G/H synthase 1 (IC50 = 1 uM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Mannitol; Ferric oxide yellow; Titanium dioxide; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | GlaxoSmithKline | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Trametinib 2 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Mannitol; Ferric oxide red; Titanium dioxide; Croscarmellose sodium; Polysorbate 80; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | GlaxoSmithKline | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Polysorbate 80 | DIG Info | Prostaglandin G/H synthase 1 (IC50 = 1 uM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Mannitol; Ferric oxide red; Ferric oxide yellow; Titanium dioxide; Croscarmellose sodium; Silicon dioxide; Hypromelloses; Microcrystalline cellulose
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Novartis Pharmaceuticals Corporation | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Trametinib 1 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Mannitol; Titanium dioxide; Croscarmellose sodium; Silicon dioxide; Cellulose, microcrystalline; Hypromelloses; Polyethylene glycols
|
|||||
Dosage Form | Oral Tablet | |||||
Company | GlaxoSmithKline | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Trametinib Dimethyl Sulfoxide eq 2mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Colloidal Silicon Dioxide; Croscarmellose Sodium; Hypromellose; Magnesium Stearate (Vegetable Source); Mannitol; Microcrystalline Cellulose; Sodium Lauryl Sulfate; Hypromellose; Polyethylene Glycol; Titanium Dioxide; Iron Oxide Red; Polysorbate 80
|
|||||
Dosage Form | Tablet | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [6] | |||
Polysorbate 80 | DIG Info | Prostaglandin G/H synthase 1 (IC50 = 1 uM) | [4] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [7] | |||
Trametinib Dimethyl Sulfoxide eq 0.5mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Colloidal Silicon Dioxide; Croscarmellose Sodium; Hypromellose; Magnesium Stearate (Vegetable Source); Mannitol; Microcrystalline Cellulose; Sodium Lauryl Sulfate; Hypromellose; Polyethylene Glycol; Titanium Dioxide; Iron Oxide Yellow
|
|||||
Dosage Form | Tablet | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [6] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [7] | |||
Trametinib Dimethyl Sulfoxide eq 1mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Colloidal Silicon Dioxide; Croscarmellose Sodium; Hypromellose; Magnesium Stearate (Vegetable Source); Mannitol; Microcrystalline Cellulose; Sodium Lauryl Sulfate; Hypromellose; Polyethylene Glycol; Titanium Dioxide
|
|||||
Dosage Form | Tablet | |||||
Company | Novartis | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [3] | |||
Hypromellose | DIG Info | Cytochrome P450 3A5 (IC50 = 19.4 uM) | [6] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [5] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [5] | |||
Polyethylene glycol 4000 | DIG Info | Albendazole monooxygenase (Inhibition ratio < 40 %) | [7] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.